5441722025-07-012025-09-305441722025-09-305441722025-03-315441722025-04-012025-09-305441722025-07-012025-09-30in-capmkt:OtherExpenses1Member5441722025-04-012025-09-30in-capmkt:OtherExpenses1Member5441722025-07-012025-09-30in-capmkt:ReportableSegments1Member5441722025-07-012025-09-30in-capmkt:ReportableSegments2Member5441722025-07-012025-09-30in-capmkt:ReportableSegments3Member5441722025-07-012025-09-30in-capmkt:ReportableSegments4Member5441722025-04-012025-09-30in-capmkt:ReportableSegments1Member5441722025-04-012025-09-30in-capmkt:ReportableSegments2Member5441722025-04-012025-09-30in-capmkt:ReportableSegments3Member5441722025-04-012025-09-30in-capmkt:ReportableSegments4Member5441722025-07-012025-09-30in-capmkt:ReportableSegments1Member5441722025-07-012025-09-30in-capmkt:ReportableSegments2Member5441722025-07-012025-09-30in-capmkt:ReportableSegments3Member5441722025-07-012025-09-30in-capmkt:ReportableSegments4Member5441722025-04-012025-09-30in-capmkt:ReportableSegments1Member5441722025-04-012025-09-30in-capmkt:ReportableSegments2Member5441722025-04-012025-09-30in-capmkt:ReportableSegments3Member5441722025-04-012025-09-30in-capmkt:ReportableSegments4Member5441722025-07-012025-09-30in-capmkt:ReportableSegments1Member5441722025-09-30in-capmkt:ReportableSegments1Member5441722025-07-012025-09-30in-capmkt:ReportableSegments2Member5441722025-09-30in-capmkt:ReportableSegments2Member5441722025-07-012025-09-30in-capmkt:ReportableSegments3Member5441722025-09-30in-capmkt:ReportableSegments3Member5441722025-07-012025-09-30in-capmkt:ReportableSegments4Member5441722025-09-30in-capmkt:ReportableSegments4Member5441722025-07-012025-09-30in-capmkt:ReportableSegments1Member5441722025-09-30in-capmkt:ReportableSegments1Member5441722025-07-012025-09-30in-capmkt:ReportableSegments2Member5441722025-09-30in-capmkt:ReportableSegments2Member5441722025-07-012025-09-30in-capmkt:ReportableSegments3Member5441722025-09-30in-capmkt:ReportableSegments3Member5441722025-07-012025-09-30in-capmkt:ReportableSegments4Member5441722025-09-30in-capmkt:ReportableSegments4Member5441722025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15441722025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15441722025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15441722025-07-012025-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544172INDGNNOTLISTEDINE065X01017Indegene LimitedMain BoardEquity2025-04-012026-03-312025-10-302025-10-23INRMillionsQuarterlySecond quarterMulti segment2025-10-3018:30:002025-10-3019:05:00trueCash Flow IndirectDeclaration of unmodified opinion2025-07-012025-09-30UnauditedConsolidated8042000000197000000823900000000051580000003800000023400000014780000006908000000133100000001331000000379000000-6900000031000000001021000000000010210000004840000001505000000001021000000048000000024.264.23004.264.23All amounts in INR millions except share data and where otherwise stated <BR> <BR> 1 The above Consolidated Financial Results of Indegene Limited the Company or the Parent or the Holding Company together with its affiliates collectively the Group have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals Caret symbol in the financial information denote amounts less than INR half a million <BR> <BR> 2 The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 29 October 2025 and approved by the Board of Directors at its meeting held on 30 October 2025 The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and six months ended 30 September 2025 and have issued an unmodified review report on the same <BR> <BR> 3 The Consolidated Financial Results for the quarter and six months ended 30 September 2025 are available on the National Stock Exchange of India Limited URL www nseindia com the BSE Limited website URL wwwbseindia com and on the Company s website URL www indegene com investor relations <BR> <BR> 4 Acquisition of MJL Communications Group Ltd <BR> On 25 March 2025 the Group had obtained control of MJL Communications Group Ltd MJL by acquiring 100 percent of its shares The acquisition was consummated for a consideration of INR 411 which includes earnout payment of INR 150 The contingent consideration is based on the performance of MJL during the fiscal year beginning 01 April 2025 and ending 31 March 2027 and range of contingent consideration payable is between Nil to INR 172 The Group has concluded that the acquisition is business and did the provisional PPA for the same during year ended 31 March 2025 which was finalised during the six months ended 30 September 2025 <BR> <BR> The fair value of net assets acquired on the acquisition date as a part of the transaction amounted to INR 98 The excess of purchase consideration over the fair value of net assets acquired has been attributed towards the identifiable intangible assets aggregating to INR 174 and goodwill aggregating to INR 139 <BR> 2025-04-012025-09-30UnauditedConsolidated1565000000041800000016068000000000997300000075000000450000000271800000013216000000285200000002852000000663000000400000066700000002185000000000021850000006510000002836000000002185000000048000000029.129.05009.129.05Other expenses1478000000Other expenses27180000001613000000003794000000178800000000000019300000019300000091200000014400000084440000000778300000078700000003683000000121500000002800000020579000000359000000637500000027313000000003575700000048000000028176000000286560000000286560000000000999000000999000000597000000000159600000002000000089500000091500000016390000002554000000203400000079200000012500000005505000000007101000000357570000006 Final dividend for the financial year 2024 25 of INR 2 per share was approved by the shareholders at the 27th Annual General Meeting held on 26 June 2025 and the same was paid on 30 June 2025 <BR> <BR> 7 As on 30 September 2025 the Group has entered into a stock purchase agreement with BioPharm Parent Holding Inc and Engage Acquisition Corp Seller to acquire 100 percent interest in BioPharm Parent Holding Inc BioPharm a specialized marketing services agency part of Omnicom Health Group for an aggregate purchase consideration of INR 9146 USD 104 million including deferred and earn out consideration with effective date being 01 October 2025 This acquisition is expected to strengthen Groups commercialization portfolio with AdTech combining AI and digital advertising enabling pharma companies to drive more precise scalable and measurable outcomes <BR> <BR> Accordingly, the Group has transferred the upfront purchase consideration of INR 5519 USD 62 million payable to the Seller as per the stock purchase agreement to the Escrow agent s account on 30 September 2025 and the same has been disclosed as part of the other current assets as on 30 September 2025 The same has been subsequently transferred to the Seller on 01 October 2025 The Group is currently in the process of allocating the purchase consideration to identifiable assets and liabilities of BioPharm <BR> <BR> 8 During the year 2020 21 the Group was named in a class action lawsuit filed in the US District Court of New Jersey alleging non compliance with the Telephone Consumer Protection Act of 1991 TCPA by sending unsolicited fax advertisements without the recipients prior express invitation or permission <BR> <BR> In July 2025 the Court allowed the case to proceed as a class action The Groups request to challenge this decision was not accepted The matter remains ongoing and is progressing toward trial or potential settlement Mediation discussions are expected in early 2026 with the Group participating on a no admission of liability basis <BR> <BR> As of 30 September 2025 no settlement terms have been proposed or agreed and the scope of potential claimants remains uncertain Any financial obligation would depend on valid claims being filed and cannot be reliably estimated Accordingly no provision is considered necessary in the consolidated financial results at this stage <BR> <BR> 9 Subsequent to the quarter and six months ended 30 September 2025 the Group has acquired 100 percent stake in the Warn and Co Limited acquired company a UK based Company providing business transformation consulting solutions around change management organisation design and solution design by way of Share Purchase agreement dated 16 October 2025 to acquire 100 percent shares of the acquired company for a purchase consideration approximating to GBP 3 millions subject to working capital adjustments <BR> <BR> Notes to Assets and Liabilites: <BR> a Property plant and equipment includes Right-of-use assets of INR 1145 <BR> b Other non-current asset consists of Non-current tax assets net of INR 106 and Other non-current asset of INR 39 <BR> c Trade receivables current consists Billed Revenue INR 6865 and Unbilled revenue of INR 1005 <BR> d Other non current financial liabilities consists of lease liabilities of INR 882 and Other financial Liabilities INR 117 <BR> e Other current financial liabilities consists of lease liabilities INR 338 and other financial liabilities of INR 1301Enterprise Medical Solutions2242000000Enterprise Commercial Solutions4874000000Brand Activation638000000Others288000000Enterprise Medical Solutions4374000000Enterprise Commercial Solutions9327000000Brand Activation1396000000Others55300000080420000001565000000000804200000015650000000Enterprise Medical Solutions575000000Enterprise Commercial Solutions1023000000Brand Activation-41000000Others-59000000Enterprise Medical Solutions1151000000Enterprise Commercial Solutions2071000000Brand Activation10000000Others-10900000014980000003123000000380000007500000012900000019600000013310000002852000000Enterprise Medical Solutions0Enterprise Commercial Solutions0Brand Activation0Others0000Enterprise Medical Solutions0Enterprise Commercial Solutions0Brand Activation0Others00005 The Segment results of the Group has been prepared in accordance with Ind AS 108 on Operating Segments The Group has identified business segments industry practice as reportable segments The reportable business segments comprise 1 Enterprise Medical Solutions 2 Enterprise Commercial Solutions 3 Brand Activation <BR> <BR> Effective 1 April 2025 the Omnichannel Activation segment has been renamed as Brand Activation <BR> Others mainly comprises of consultancy and clinical business <BR> <BR> Notes on Segment information <BR> Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker In deciding how to allocate resources and assessing performance the Groups chief operating decision maker is the Chief Executive Officer and Executive Director <BR> <BR> Assets and liabilities used in the Groups business are not identified to any of the operating segments as these are used interchangeably between segments Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous <BR> <BR> Other unallocable expenditure net of unallocable income for the three months ended 30 Sep 2025 includes depreciation and amortisation expense INR 234 and unallocable expenses INR 93 net of other income INR 197 <BR> <BR> Other unallocable expenditure net of unallocable income for the Six months ended 30 Sep 2025 includes depreciation and amortisation expense INR 450 and unallocable expenses INR 164 net of other income INR 418 <BR> <BR> Statement of Cash Flow includes following aggregations <BR> 1 Cash flows from Operating Activities <BR> Other adjustments to reconcile profit loss includes <BR> a Gain on termination of lease negative INR 3 <BR> b Loss on sale of fixed assets negative INR 1 <BR> c Net gain on disposal fair valuation of investments negative INR 187 <BR> d Expected credit loss on trade receivables and advances negative INR 1 <BR> e Bad debts written off negative INR 1 <BR> <BR> 2 Cash flows from Investing Activities <BR> Other Inflow Outflows of cash includes <BR> a Purchase of investments accounted using FVTPL negativeINR 20516 <BR> b Proceeds from redemption of investments INR 25817 <BR> c Investments in fixed deposits negative INR 1968 <BR> d Redemption or maturity of fixed deposit INR 2089 <BR> <BR> Other cash payments to acquire equity or debt instruments of other entities consists of Amount Trasfer to Escrow agent for acquisition INR 5519 <BR> <BR> 3 Cash flows from Financing Activities <BR> Proceeds from issuing shares is net of share issue expenses590000000-200000000192000000000000-35200000004500000000152000000000-40000000235000000115000000000-19300000000164000000301600000000098800000002028000000000551900000000000157000000000000000000000000286000000054220000003200000000280000000000000183000000480000000100000000-6360000001424000000-151000000127300000024100000003683000000Remeasurement of defined benefit obligation2400000024000000Remeasurement of defined benefit obligation360000003600000060000009000000Exchange differences on translating the financial statements of foreign operations466000000466000000Exchange differences on translating the financial statements of foreign operations62400000062400000000484000000651000000UnauditedtrueDeloitte Haskins & Sellstrue2028-04-30